{
    "@xmlns:dc": "http://purl.org/dc/elements/1.1/",
    "dc:title": "Proceedings/Doxazosin: a distinctive approach to risk reduction of coronary heart disease in hypertensive patients, symposium, Hamburg, West Germany, January 30, 1988",
    "dc:creator": "HAYDUK, K",
    "dc:contributor": [
        "Pfizer International (Funder/Sponsor)",
        "Doxazosin: a distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Symposium (1988-01-30)"
    ],
    "dc:relation": "The American heart journal -- Am. heart j, CODEN AHJOA2, ISSN 0002-8703, Vol. 116 (6) , pp. 1707-1840",
    "dc:date": "1988",
    "dc:type": [
        "Text",
        "Conference Proceedings"
    ],
    "dc:language": "English",
    "dc:publisher": "Elsevier",
    "dc:format": [
        "print",
        "dissem"
    ],
    "dc:subject": [
        {
            "@xml:lang": "fr",
            "#text": "Appareil circulatoire pathologie"
        },
        {
            "@xml:lang": "fr",
            "#text": "Bloquant α-adrénergique"
        },
        {
            "@xml:lang": "fr",
            "#text": "Cardiopathie coronaire"
        },
        {
            "@xml:lang": "fr",
            "#text": "Chimiothérapie"
        },
        {
            "@xml:lang": "fr",
            "#text": "Congrès"
        },
        {
            "@xml:lang": "fr",
            "#text": "Doxazosine"
        },
        {
            "@xml:lang": "fr",
            "#text": "Homme"
        },
        {
            "@xml:lang": "fr",
            "#text": "Hypertension artérielle"
        },
        {
            "@xml:lang": "fr",
            "#text": "Récepteur α1-adrénergique"
        },
        {
            "@xml:lang": "fr",
            "#text": "Traitement"
        },
        {
            "@xml:lang": "en",
            "#text": "Cardiovascular disease"
        },
        {
            "@xml:lang": "en",
            "#text": "Alpha blocking agent"
        },
        {
            "@xml:lang": "en",
            "#text": "Coronary heart disease"
        },
        {
            "@xml:lang": "en",
            "#text": "Chemotherapy"
        },
        {
            "@xml:lang": "en",
            "#text": "Congress"
        },
        {
            "@xml:lang": "en",
            "#text": "Human"
        },
        {
            "@xml:lang": "en",
            "#text": "Hypertension"
        },
        {
            "@xml:lang": "en",
            "#text": "α1-Adrenergic receptor"
        },
        {
            "@xml:lang": "en",
            "#text": "Treatment"
        },
        {
            "@xml:lang": "es",
            "#text": "Aparato circulatorio patología"
        },
        {
            "@xml:lang": "es",
            "#text": "Bloqueador α-adrenérgico"
        },
        {
            "@xml:lang": "es",
            "#text": "Cardiopatía coronaria"
        },
        {
            "@xml:lang": "es",
            "#text": "Quimioterapia"
        },
        {
            "@xml:lang": "es",
            "#text": "Congreso"
        },
        {
            "@xml:lang": "es",
            "#text": "Hombre"
        },
        {
            "@xml:lang": "es",
            "#text": "Hipertensión arterial"
        },
        {
            "@xml:lang": "es",
            "#text": "Receptor α1-adrenérgico"
        },
        {
            "@xml:lang": "es",
            "#text": "Tratamiento"
        },
        "002B02F05: Antihypertenseurs / Antihypertensive agents"
    ],
    "dc:rights": [
        "Inist-CNRS",
        "Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS"
    ],
    "dc:identifier": "Inist-CNRS record number 7061966"
}